文档介绍：小细胞肺癌的化疗
Cancer
Network
NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines
Small Cell Lung
Cancer
NCCN. org
全球每年新诊断肺癌患者约140万
小细胞肺癌约占肺癌的15-20%;且近年来呈下降趋势(30%-15%
SEER数据),可能与新病理分类有关
·美国癌症研究院18%
我国港台地区
14%
·大陆地区
10-15%
口约6%的小细胞肺癌诊断时为广泛期(ES-SCLC),局限期(LS-SCLC仅
不到40%
Pugisi M et al B/C 2010 102629-638 Zhu H ef al Cancer, 2011 Dec I 117(23)15423-31
口小细胞肺癌患者的预后差,进屐快,早期扩散
口对放化疗敏感, ED SCLO化疗有效达70%, LD SCLO甚至高达
90%(CR45~75%)
但易出现耐药及复发(1年内复发率75~90%)
D-SCLC
ED-SCLC
中位生存期
15-20个月
8-13个月
2年生存率
20%40%
<5%
5年生存率
10%-13%
1%-2%
oogt20s61291096-104
survival of sclc
marginally improvement of survival in 2 decades
Median survival seer database
77147576777的粒B赫的的静9创翰
76788第899
Limited Disease(lanne et al. Cancer 2002)
Extensive Disease( Chute et al. JClin Oncol 1999)
SCLC的预后因素
·Ps3,4、广泛期、体重、LDH个是最重要的预后不良因素
局限期:女性、<70岁、LDH水平不高、I是预后良好指标
广泛期:年轻、一般状况好、肌酐及LDH水平不高、单一转移病
灶是预后良好指标
细胞肺癌临床分期
Comprehensive NCCN Guidelines Version 1. 2015 Staging
NCCN Network. Small Cell Lung Cancer
be safely temed wh ofneW radation does Exudes 134 due b mump tngt
JCC (uh eaton) Stage M(T any, N a的a门比
movement by
ounded by kung or visco
nodules)n corealteral kee t
n exton to the
Mib D
yy amino
mediastinum, heart
geat vessels trachea
National
mprehensive NCCN Guidelines Version 1,.2015
tork Small Cell Lung Cancer
SCLC Table of Conte
INITIAL EVALUATION
STAGE
CBC with differential, platelets
ST-1 for TNM
ILFTs) Ca, LDH
N. creatinine
est adrenal CT with IV
nswe stage
PTCT轼Mn团 limited stage is
sT′ or TNM
Treatment(SCLI
Smoking cessation counseling and
sta)e s estabished, further staging ewauson is optoma. Howewer, bran ma. MA preemed) or cT wmh N contrast shoul be obtaned nal
etastases Patobgc corfrmaon s recommended for sons seeded by PETNCT that ater stage
All neoommentahons Me CatEgory 2A U
0
SCL.
National
Comprehensive NCCN Guidelines Version
NCCN Cancer
Small Cell Lung Cancer
C Table of